Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of gemtuzumab ozogamicin plus ATRA, high-dose cytarabine and mitoxantrone in primary refractory AML (GO-A-HAM)
2004-003739-30Phase 2Completed
- Sponsor
- University Hospital Ulm
- Start
- Sep 2005
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by University Hospital Ulm. Primary endpoint: Complete remission rate. Started Sep 2005; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2004-003739-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003739-30.